Akeso Biopharma, Inc.
Akeso Biopharma, Inc., a leading biopharmaceutical company headquartered in China, is at the forefront of innovative drug development. Founded in 2012, Akeso has rapidly established itself within the biotechnology industry, focusing on the research, development, and commercialisation of monoclonal antibodies and other biologics. With a strong presence in major operational regions across Asia and beyond, Akeso is renowned for its unique portfolio of core products, including innovative therapies for oncology and autoimmune diseases. The company has achieved significant milestones, including successful clinical trials and partnerships that enhance its market position. Akeso's commitment to advancing healthcare through cutting-edge biopharmaceutical solutions underscores its reputation as a key player in the global biopharma landscape.
DitchCarbon Score
How does Akeso Biopharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Akeso Biopharma, Inc.'s score of 0 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Akeso Biopharma, Inc.'s reported carbon emissions
Akeso Biopharma, Inc., headquartered in China (CN), currently does not have publicly available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is challenging to assess their climate impact or sustainability efforts. However, the biopharmaceutical industry is increasingly focusing on reducing carbon footprints and enhancing sustainability practices. Akeso Biopharma may be engaging in industry-standard climate initiatives, but further information would be required to provide a comprehensive overview of their commitments and performance in this area.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Akeso Biopharma, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
